Rocket Pharmaceuticals, Inc. (RCKT)
NASDAQ: RCKT · Real-Time Price · USD
10.47
-0.40 (-3.68%)
At close: Feb 21, 2025, 4:00 PM
10.66
+0.19 (1.81%)
After-hours: Feb 21, 2025, 7:16 PM EST
Rocket Pharmaceuticals Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for Rocket Pharmaceuticals stock have an average target of 48.8, with a low estimate of 29 and a high estimate of 65. The average target predicts an increase of 366.09% from the current stock price of 10.47.
Analyst Consensus: Strong Buy
* Price targets were last updated on Dec 18, 2024.
Analyst Ratings
The average analyst rating for Rocket Pharmaceuticals stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 5 | 5 | 5 |
| Buy | 3 | 4 | 5 | 5 | 5 | 4 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 9 | 10 | 11 | 11 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jefferies | Jefferies | Strong Buy Initiates $29 | Strong Buy | Initiates | $29 | +176.98% | Dec 18, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $39 | Strong Buy | Maintains | $39 | +272.49% | Nov 19, 2024 |
| Leerink Partners | Leerink Partners | Buy Maintains $46 → $44 | Buy | Maintains | $46 → $44 | +320.25% | Nov 19, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $65 | Buy | Reiterates | $65 | +520.82% | Nov 19, 2024 |
| Needham | Needham | Strong Buy Reiterates $52 | Strong Buy | Reiterates | $52 | +396.66% | Nov 19, 2024 |
Financial Forecast
Revenue This Year
26.60K
Revenue Next Year
59.93M
from 26.60K
Increased by 225,168.40%
EPS This Year
-2.84
from -2.92
EPS Next Year
-2.27
from -2.84
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 328,650 | 262.4M | 562.9M | |||
| Avg | 26,602 | 59.9M | 226.2M | |||
| Low | n/a | n/a | 7.3M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | 986,269.2% | 839.4% | |||
| Avg | - | 225,168.4% | 277.5% | |||
| Low | - | - | -87.8% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -2.57 | -0.66 | 0.32 | |||
| Avg | -2.84 | -2.27 | -1.54 | |||
| Low | -2.89 | -3.14 | -2.84 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.